Related Experiment Video

Updated: Jun 27, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy

Yeteng Mu1,2, Xingang Guan1

  • 1Department of Basic Medicine, School of Medicine, Taizhou University, Taizhoum, 318000, Zhejiang Province, China.

Current Medicinal Chemistry
|April 26, 2024
PubMed

Insights

Novel immune checkpoint inhibitors targeting the TIGIT pathway show promise for improving cancer immunotherapy response rates and overcoming drug resistance. Disrupting the CD155-TIGIT axis may enhance antitumor immunity.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors (ICIs) offer significant cancer treatment efficacy but face limitations like low response rates, immune-related adverse events (irAEs), and drug resistance.
  • Novel immunotherapies are crucial for improving outcomes in advanced cancer patients.

Purpose of the Study:

  • To review the role of T-Cell immunoglobulin and ITIM domain (TIGIT) in tumor immune escape.
  • To summarize the preclinical and clinical development of drugs targeting the CD155-TIGIT axis for cancer immunotherapy.

Main Methods:

  • Literature review of studies on TIGIT function in cancer.
  • Analysis of preclinical and clinical trial data for CD155-TIGIT targeting agents.

Main Results:

  • TIGIT is an inhibitory receptor on immune cells that contributes to tumor immune escape.
  • Disrupting the CD155-TIGIT interaction shows potential for immune system activation and restoration of antitumor responses.
  • Targeting this axis is under investigation in various preclinical and clinical cancer immunotherapy trials.

Conclusions:

  • Targeting the CD155-TIGIT axis represents a promising strategy for novel cancer immunotherapies.
  • Further development of TIGIT-targeting drugs may overcome current ICI limitations and improve patient survival.
Keywords:
CD155PD-1TIGITcancer immunotherapyimmune checkpoint inhibitortumor cells.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

498
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
359
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K